Sign In
Buy ZVSA
$0.170
+0 (+0%)
At Close: Jun 03, 2026
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
04:55pm, Wednesday, 13'th May 2026
LIGHTHOUSE POINT, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for the treatmen
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
05:05pm, Tuesday, 31'st Mar 2026
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion. Inflammasome ASC Inhibitor IC 100 is a next generation d
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 65.4% – Still a Buy?
02:06am, Saturday, 10'th Jan 2026
Shares of ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA - Get Free Report) shot up 65.4% during mid-day trading on Friday. The company traded as high as $0.2670 and last traded at $0.2652. 1,507,772 shares
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
04:20pm, Wednesday, 19'th Nov 2025
WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for tre
Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.
Lipid alterations in Alport syndrome are linked to impaired ABCA1 lipid efflux and the underlying renal injury processes of lipotoxicity and inflammation.
Lipid accumulation in the kidneys' filtration system results in inflammation and fibrosis that cause progressive kidney damage and disease progression.
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
09:00am, Wednesday, 13'th Aug 2025
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
07:55am, Monday, 21'st Jul 2025
WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
01:48pm, Tuesday, 08'th Jul 2025
ZyVersa Therapeutics, Inc. ZVSA stock was trading higher on Tuesday, with a session volume of 160.9 million compared to the average volume of 4.03 million as per data from Benzinga Pro.
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
12:30pm, Tuesday, 08'th Jul 2025
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into th
Site initiation for Phase 2a DKD trial marks a key milestone for ZyVersa, and for development of VAR 200, a first-in-class treatment for kidney disease.
WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treat
Study results corroborate our recently published data demonstrating the critical role of microglial-driven inflammation in promoting accumulation and spread of toxic phosphorylated alpha-synuclein lea
